George Z Retsch-Bogart

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. doi request reprint Update on new pulmonary therapies
    George Z Retsch-Bogart
    Division of Pulmonology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7217, USA
    Curr Opin Pulm Med 15:604-10. 2009
  2. ncbi request reprint A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection
    George Z Retsch-Bogart
    Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7220, USA
    Pediatr Pulmonol 43:47-58. 2008
  3. pmc Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis
    George Z Retsch-Bogart
    Department of Pediatrics, University of North Carolina, Chapel Hill, NC 27599 7217, USA
    Chest 135:1223-32. 2009
  4. ncbi request reprint Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis
    Claudia L Ordonez
    Department of Pediatrics, Harvard Medical School, Boston, MA 02215, USA
    Am J Respir Crit Care Med 168:1471-5. 2003
  5. ncbi request reprint Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, University of Washington, Children s Hospital and Regional Medical Center, Seattle, Washington 98105 0371, USA
    Pediatr Pulmonol 41:656-65. 2006
  6. ncbi request reprint Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis
    Stephanie D Davis
    Division of Pediatric Pulmonology, Chapel Hill, NC 27599 7220, USA
    Am J Respir Crit Care Med 175:943-50. 2007

Detail Information

Publications6

  1. doi request reprint Update on new pulmonary therapies
    George Z Retsch-Bogart
    Division of Pulmonology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7217, USA
    Curr Opin Pulm Med 15:604-10. 2009
    ..This review focuses on the most notable clinical trials of pulmonary therapies reported in the last year...
  2. ncbi request reprint A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection
    George Z Retsch-Bogart
    Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7220, USA
    Pediatr Pulmonol 43:47-58. 2008
    ..Aztreonam lysine for inhalation (AZLI) is being developed for treatment of CF patients with Pseudomonas aeruginosa airway infection...
  3. pmc Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis
    George Z Retsch-Bogart
    Department of Pediatrics, University of North Carolina, Chapel Hill, NC 27599 7217, USA
    Chest 135:1223-32. 2009
    ..We assessed the short-term efficacy and safety of aztreonam lysine for inhalation (AZLI [an aerosolized monobactam antibiotic]) in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA) airway infection...
  4. ncbi request reprint Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis
    Claudia L Ordonez
    Department of Pediatrics, Harvard Medical School, Boston, MA 02215, USA
    Am J Respir Crit Care Med 168:1471-5. 2003
    ..Seven of 127 (6%) sputum induction procedures showed a decrease in FEV1 of 20% or more. We conclude that markers in induced sputum may be useful, noninvasive outcome measures to assess response to therapies in cystic fibrosis studies...
  5. ncbi request reprint Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, University of Washington, Children s Hospital and Regional Medical Center, Seattle, Washington 98105 0371, USA
    Pediatr Pulmonol 41:656-65. 2006
    ..Aztreonam lysinate for inhalation (AI) is a novel monobactam formulation being investigated for pulmonary Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF)...
  6. ncbi request reprint Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis
    Stephanie D Davis
    Division of Pediatric Pulmonology, Chapel Hill, NC 27599 7220, USA
    Am J Respir Crit Care Med 175:943-50. 2007
    ..Detecting and tracking early cystic fibrosis (CF) lung disease are difficult due to lack of sensitive markers of airway dysfunction...